A Look at Bio-Rad Laboratories’s Valuation Following New StarBright Dye Launch for Flow Cytometry

Bio-Rad Laboratories (BIO) has announced the launch of four new StarBright dyes, which are intended to improve multiplexing in flow cytometry. These additions are designed to help researchers obtain higher quality data and provide greater flexibility.

See our latest analysis for Bio-Rad Laboratories.

Bio-Rad Laboratories’ launch of the new StarBright dyes arrives as the company seeks renewed momentum. Its share price stands at $324.86, having gained an encouraging 11.75% over the past 90 days. However, total shareholder return for the past year is down 4.11 percent, with longer-term returns showing steeper declines. As a result, recent gains are being watched for signs of a genuine turnaround rather than just a temporary bounce.

If you’re inspired by how scientific breakthroughs can move the market, the next step is to check out other promising companies through our dedicated See the full list for free.

With shares still trading roughly 17 percent below analyst estimates and a mixed track record over the past year, investors may wonder whether Bio-Rad is undervalued or if the market already anticipates its next phase of growth.

Most Popular Narrative: 6.6% Undervalued

Compared to its latest share price of $324.86, the most widely followed narrative sets Bio-Rad Laboratories’ fair value at $348. A modest upside remains, setting expectations for what comes next.

Recent launch and expansion of the QX Continuum and QX700 Series ddPCR platforms, alongside the acquisition of Stilla Technologies, positions Bio-Rad to accelerate its share capture as demand grows for advanced molecular diagnostics and precision medicine tools. This is expected to drive ddPCR revenue growth and improve margins through higher consumable pull-through and broader assay adoption.

Read the complete narrative.

Want to know why this narrative leans bullish despite a challenging market? The answer lies in a fresh revenue mix and bold long-term profit assumptions. Which trends, partnerships, and strategic moves underpin the story? Find out what’s behind the optimism and see the math that fuels this valuation.

Result: Fair Value of $348 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent weak instrument demand and policy changes in key markets could affect Bio-Rad’s revenue growth and create challenges for its margin outlook.

Find out about the key risks to this Bio-Rad Laboratories narrative.

Build Your Own Bio-Rad Laboratories Narrative

If you have a different perspective or want to interpret the figures for yourself, you can build a customized narrative in just a few minutes. Do it your way

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Bio-Rad Laboratories.

Looking for more investment ideas?

Now is the perfect time to go beyond the obvious. Find opportunities others might miss and position yourself ahead of the curve with just a few clicks.

• Tap into profit potential by reviewing these 915 undervalued stocks based on cash flows that analysts believe the market is currently overlooking. See which stocks show the best value for their fundamentals.
• Supercharge your portfolio by eyeing these 25 AI penny stocks benefiting from artificial intelligence breakthroughs and emerging trends in advanced machine learning.
• Unlock consistent income streams as you review these 15 dividend stocks with yields > 3% known for strong yields and reliable dividend histories. This can help you grow wealth with less guesswork.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com